Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up

Onkologie

Volumn 31, Issue 7, 2008, Pages 366-372

  Bader, Franz G ^a,b   Lordick, Florian ^c   Fink, Ulrich ^d   Becker, Karen ^d   Höfler, Heinz ^d   Busch, Raymonde ^d   Siewert, Jörg R ^e   Ott, Katja ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e NONE

Author keywords

Adenocarcinoma of the esophagus; Neoadjuvant chemotherapy; Paclitaxel

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHYLOTHORAX; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FACIAL NERVE PARALYSIS; FATIGUE; FEMALE; FOLLOW UP; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NERVE PARALYSIS; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; SEPSIS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX INCOMPETENCE; VOMITING; WOUND INFECTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; TREATMENT OUTCOME;

EID: 47049120242     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135515     Document Type: Article

References (26)

1. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouche O, Segol P, Bedenne L, Rougier P, Ychou M: Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of the stomach and lower esophagus. J Clin Oncol 2007;25:18S.
2. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
3. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984.
4. Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B: Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2007;67:397-404.
5. Lowy AM, Firdaus I, Roychowdhury D, Redmond K, Howington JA, Sussman JJ, Safa M, Ahmad SA, Reed MF, Rose P, James L, Jazieh AR: A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma. Am J Clin Oncol 2006;29:555-561.
6. Roof KS, Coen J, Lynch TJ, Wright C, Fidias P, Willett CG, Choi NC: Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2006;65:1120-1128.
7. Weiner LM, Colarusso P, Goldberg M, Dresler C, Coia LR: Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 1997;24:S19-93-S19-95.
8. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234.
9. Heidecke CD, Weighardt H, Feith M, Fink U, Zimmermann F, Stein HJ, Siewert JR, Holzmann B: Neoadjuvant treatment of esophageal cancer: immunosuppression following combined radiochemotherapy. Surgery 2002;132:495-501.
10. Reynolds JV, Ravi N, Hollywood D, Kennedy MJ, Rowley S, Ryan A, Hughes N, Carey M, Byrne P: Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2006;132:549-555.
11. Höhler T, Rödel C, Hölscher A, Al-Batran S: Neoadjuvante und palliative Therapie des Ösophagus-und Magenkarzinoms. Onkologie 2007;30(suppl 2):23-26.
12. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826-1834.
13. Laack E, Andritzky B, Durk H, Burkholder I, Edler L, Schuch G, Boeters I, Gorn M, Lipp R, Horst H, Popp J, Hossfeld DK: Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie 2005;28:647-650.
14. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
15. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB: In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-446.
16. Steren A, Sevin BU, Perras J, Ramos R, Angioli R, Nguyen H, Koechli O, Averette HE: Taxol as a radiation sensitizer: a flow cytometric study. Gynecol Oncol 1993;50:89-93.
17. Bartels H, Stein HJ, Siewert JR: Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 1998;85:840-844.
18. Bartels H, Stein HJ, Siewert JR: Risk analysis in esophageal surgery. Recent Results Cancer Res 2000;155:89-96.
19. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U: Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6:159-167.
20. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-4698.
21. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
22. Chak A, Canto MI, Cooper GS, Isenberg G, Willis J, Levitan N, Clayman J, Forastiere A, Heath E, Sivak MV Jr: Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 2000;88:1788-1795.
23. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999;229:303-308.
24. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-1530.
25. Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, DeCamp M, Vargo JJ, Dumot JA, Zuccaro G: Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000;18:2032-2039.
26. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007;18:1673-1679.